Mukul Agrawal trimmed his stake in Strides Pharma Science, selling 37,250 shares. His holding decreased from 1.16% (1,066,000 shares) to 1.12% (1,028,750 shares). The value of the sold shares was approximately ₹4.01 crore based on the closing price of ₹1074.90 apiece.
A pharmaceutical manufacturer engaged in developing and producing a diverse range of drug formulations for global distribution. The company operates across multiple therapy segments and maintains manufacturing facilities serving customers in over 100 countries. Strides Pharma has pursued strategic acquisitions and inorganic expansion to strengthen its market presence, diversify business segments, enhance therapy offerings, and build robust production infrastructure.
Started trading IPO grey markets as a teenager in Jaipur, founded Param Capital in 1993, and has quietly built one of the largest publicly trackable individual equity books in India, ~₹7,100 Cr across 63 listed companies. Neuland Laboratories is one of his legendary calls, delivering multiples for patient followers. Radico Khaitan, AMS Technologies, he finds quality businesses and holds. Sector-agnostic, conviction-heavy, and consistently early.